Epilepsiae

The project intends to develop an intelligent alarming system, transportable by the patient, measuring the brain dynamical activity, capable of predicting the seizures, allowing the patient to assess the risk of his actual situation and improving his safety The system is based on multi-signal information (EEG, ECG and others), intelligent data processing and wireless communications.

The project will develop knowledge (in data analysis), algorithms (of seizure prediction) and technologies (of data acquisition and wireless transmission) that integrated into an intelligent system will be an important step forward in economical affordable personal healthcare systems for neurological applications. A distributed European Epilepsy Database will also be built by the project, including all the available information about epileptic patients, allowing semantic mining based on multi-modal, multisignal and multidimensional data.

The Epilepsiae consortium consists of seven partners from 4 countries: 3 academic, 3 clinics, 1 industrial SME company, covering the whole value chain from theoretical conception to market products and final users.

For further information, please visit:
http://www.epilepsiae.eu

Project co-ordinator:
FACULDADE CIENCIAS E TECNOLOGIA DA UNIVERSIDADE DE COIMBRA (Portugal)

Partners:

  • ALBERT-LUDWIGS-UNIVERSITAET FREIBURG (Germany)
  • MICROMED S.P.A. (Italy)
  • UNIVERSITAETSKLINIKUM FREIBURG (Germany)
  • CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
  • HOSPITAIS DA UNIVERSIDADE DE COIMBRA (Portugal)

Timetable: from 01/2008 – to 12/2010

Total cost: €4.153.125

EC funding: €2.919.805

Programme Acronym: FP7-ICT

Subprogramme Area: Advanced ICT for risk assessment and patient safety

Contract type: Collaborative project (generic)

Related news article:

Most Popular Now

Open Call HORIZON-MISS-2022-CANCER-01-04…

The overall goal of the Mission on Cancer[1] and the Europe's Beating Cancer Plan[2] includes a better quality of life for patients and their families living with, and after, cancer. Project...

Insilico Medicine Raises $60 Million in …

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a $60 million Series D financing from a syndicate of global investors with...

Researchers Use AI to Predict Cancer Ris…

An artificial intelligence (AI) tool helps doctors predict the cancer risk in lung nodules seen on CT, according to a new study published in the journal Radiology. Pulmonary nodules appear as...

KTU Researchers Investigate the Links Be…

In recent years Alzheimer's disease has been on the rise throughout the world and is rarely diagnosed at an early stage when it can still be effectively controlled. Using artificial...

Speech Analysis App Predicts Worsening H…

A voice analysis app used by heart failure patients at home recognises fluid in the lungs three weeks before an unplanned hospitalisation or escalation in outpatient drug treatment. The late...

Screening for Diabetic Retinopathy Prove…

Both telemedicine and community screening for diabetic retinopathy (DR) in rural and urban settings are cost-effective in China, and telemedicine screening programs are more cost-effective, according to a study led...

Philips' Future Health Index 2022 Report…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the publication of its Future Health Index (FHI) 2022 report: 'Healthcare hits reset: Priorities shift as...

Researchers Develop Smartphone-Powered M…

A University of Minnesota Twin Cities research team has developed a new microfluidic chip for diagnosing diseases that uses a minimal number of components and can be powered wirelessly by...

App Detecting Jaundice in Babies a Succe…

A smartphone app that identifies severe jaundice in newborn babies by scanning their eyes could be a life-saver in areas that lack access to expensive screening devices, suggests a study...

InterSystems Wins Data Driven Product of…

InterSystems, a provider of next-generation solutions for enterprise digital transformation to help customers solve the most critical data challenges, has announced it received the prestigious Data Driven Product of the...

Siemens Healthineers Introduces Symbia P…

Siemens Healthineers introduces Symbia Pro.specta™, a single-photon emission computed tomography/computed tomography (SPECT/CT) system with CE Mark and Food and Drug Administration (FDA) clearance that has advanced SPECT and CT imaging...